Vident Advisory’s Recursion Pharmaceuticals RXRX Stock Holding History

Vident Advisory's RXRX Position: Q1 2026 in Review

Vident Advisory opened a new position in Recursion Pharmaceuticals (RXRX) in Q1 2026: 14,049 shares worth $43.1K. The stake represents ﹤0.01% of the portfolio and ranks #1828 among its holdings. This is a return to the name: Vident Advisory previously reported a position in RXRX as recently as Q1 2025.

Vident Advisory first reported a position in RXRX in Q3 2023 and has held it in 7 quarters since. The position peaked at $208K in Q3 2023. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

• Vident Advisory held 14,049 shares of Recursion Pharmaceuticals worth $43.1K as of Q1 2026.
• Recursion Pharmaceuticals was a new Vident Advisory position in Q1 2026.
• Recursion Pharmaceuticals made up ﹤0.01% of Vident Advisory's portfolio in Q1 2026, its #1828 holding.
• Vident Advisory first reported a position in Recursion Pharmaceuticals in Q3 2023 and has held it in 7 quarters since.
• Vident Advisory's Recursion Pharmaceuticals position peaked at $208K in Q3 2023.
• 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Vident Advisory's 13F filing for Q1 2026, filed 15 May 2026.